Details of the Drug Reposition

General Information of This Drug (ID: DM4ZP3W)

Drug Name
Heparin   DM4ZP3W
Synonyms
enoxaparin; Ardeparin; Bemiparin; SEMULOPARIN; Lovenox; LMWH; Nadroparin; Nadroparine; Reviparin; Clivarin; Sublingula; Sandoparin; Parvoparin; Parnaparin; Novoheparin; Adomiparin; Tinzaparin; Multiparin; Hepathrom; Heparina; Triofiban; Pularin; Liquemin; Heparinum; Subeparin; PK-10169; Pabyrin; Octaparin; Liquaemin; Heparine; Vetren; Fluxum; Hed-heparin; Depo-Heparin; Lipo-hepin; Fragmin A; Fragmin B; Vitrum AB; Heparin [BAN]; Eparina [DCIT]; CY 216; Adomiparin [USAN]; FR 860; Heparin CY 216; Heparine [INN-French]
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
10 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Bacteremia DIS6N9RZ 1A73 Approved [1]
Aplastic anemia DISJRSC0 3A70 Approved [1]
Disseminated intravascular coagulation DISCAVOZ 3B20 Approved [1]
Metabolic disorder DIS71G5H 5C50-5D2Z Approved [1]
Venous thrombosis DISVHK7H BA43 Approved [2]
Coronary heart disease DIS5OIP1 BA80.Z Approved [1]
Pulmonary embolism DISJYP9B BB00 Approved [1]
Deep vein thrombosis DISD8N1U BD71 Approved [1]
Pneumonia DIS8EF3M CA40 Approved [1]
Burns DISA0PR2 N.A. Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 Indications(s)
1 Discontinued in Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Malignant neoplasm DISS6SNG 2A00-2F9Z Discontinued in Phase 1 [3]
------------------------------------------------------------------------------------
2 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Investigative [4]
Diabetic angiopathy DISW0TD6 BD53.Y Investigative [1]
------------------------------------------------------------------------------------

References

1 Heparin FDA Label
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 090809.
3 Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy
4 Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020 Dec;9(1):727-732.